Background Prostate-specific membrane antigen (PSMA) PET is highly sensitive in
identifying disease recurrence in men with biochemical recurrence of prostate cancer (BCR) …

Background National guidelines endorse fluorine 18 (18F) fluciclovine PET/CT for the
detection of prostate cancer (PCa) in men with biochemically recurrent PCa. The …

Purpose To prospectively compare diagnostic accuracies for detection of bone metastases
by 68 Ga-PSMA PET/CT, 18 F-NaF PET/CT and diffusion-weighted MRI (DW 600-MRI) in …

Objectives To systematically assess the early detection rate of biochemical prostate cancer
recurrence using choline, fluciclovine, and PSMA. Methods Under the guidance of the …

Background Innovations in treatments, imaging and molecular characterisation have
improved outcomes for people with advanced prostate cancer; however, many aspects of …

Prostate cancer is the most common cancer among men and the second leading cause of
cancer-related death. For patients who develop metastatic disease, tissue-based and …

Although prostate cancer is the type of cancer most commonly survived by men in the United
States, it remains the second most common cause of death from cancer, largely owing to …

Simple Summary Prostate-specific membrane antigen positron emission tomography (PSMA
PET) is a modern imaging modality used in the management of patients with prostate cancer …

Up to 50% of patients initially treated for prostate cancer in a curative intent experience
biochemical recurrence, possibly requiring adjuvant treatment. However, salvage treatment …

Recurrence of prostate cancer after initial treatment with radiation therapy (RT) is highly
dependent on pretreatment risk group and unfortunately, a proportion of patients fail primary …